Literature DB >> 23636230

Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group.

M Hiligsmann1, M Salas, D A Hughes, E Manias, F H Gwadry-Sridhar, P Linck, W Cowell.   

Abstract

This study aims to systematically review, critically appraise and identify from the published literature, the most effective interventions to improve medication adherence in osteoporosis. A literature search using Medline, EMBASE, Cochrane library, and Cumulative Index to Nursing and Allied Health Literature was undertaken to identify prospective studies published between January 1, 1999 and June 30, 2012. We included studies on adult users of osteoporosis medications that tested a patient adherence intervention (e.g., patient education, intensified patient care, different dosing regimens) and reported quantitative results of adherence. The Delphi list was modified to assess the quality of studies. Of 113 articles identified, 20 studies fulfilled the inclusion criteria. The most frequent intervention was education (n = 11) followed by monitoring/supervision (n = 4), drug regimens (n = 2), drug regimens and patient support (n = 1), pharmacist intervention (n = 1), and electronic prescription (n = 1). Although patient education improved medication adherence in four studies, two large-scale randomized studies reported no benefits. Simplification of dosing regimens (with and without patient support program) was found to have a significant clinical impact on medication adherence and persistence. Monitoring/supervision showed no impact on medication persistence while electronic prescription and pharmacist intervention increased medication adherence or persistence. In conclusion, this review found that simplification of dosing regimens, decision aids, electronic prescription, or patient education may help to improve adherence or persistence to osteoporosis medications. We identified wide variation of quality of studies in the osteoporosis area. The efficacy of patient education was variable across studies, while monitoring/supervision does not seem an effective way to enhance medication adherence or persistence.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23636230     DOI: 10.1007/s00198-013-2364-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  39 in total

1.  Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate.

Authors:  D L Kendler; M R McClung; N Freemantle; M Lillestol; A H Moffett; J Borenstein; S Satram-Hoang; Y-C Yang; P Kaur; D Macarios; S Siddhanti
Journal:  Osteoporos Int       Date:  2010-09-09       Impact factor: 4.507

Review 2.  A framework for planning and critiquing medication compliance and persistence research using prospective study designs.

Authors:  Femida H Gwadry-Sridhar; Elizabeth Manias; Ying Zhang; Anuja Roy; Kristina Yu-Isenberg; Dyfrig A Hughes; Michael B Nichol
Journal:  Clin Ther       Date:  2009-02       Impact factor: 3.393

3.  The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients.

Authors:  Mickaël Hiligsmann; Véronique Rabenda; Olivier Bruyère; Jean-Yves Reginster
Journal:  Health Policy       Date:  2010-02-13       Impact factor: 2.980

4.  Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.

Authors:  P S M Lai; S S Chua; Y Y Chew; S P Chan
Journal:  J Clin Pharm Ther       Date:  2010-10-26       Impact factor: 2.512

5.  Use of a decision aid to improve treatment decisions in osteoporosis: the osteoporosis choice randomized trial.

Authors:  Victor M Montori; Nilay D Shah; Laurie J Pencille; Megan E Branda; Holly K Van Houten; Brian A Swiglo; Rebecca L Kesman; Sidna M Tulledge-Scheitel; Thomas M Jaeger; Ruth E Johnson; Gregory A Bartel; L Joseph Melton; Robert A Wermers
Journal:  Am J Med       Date:  2011-06       Impact factor: 4.965

6.  Patient education in groups increases knowledge of osteoporosis and adherence to treatment: a two-year randomized controlled trial.

Authors:  Dorthe Nielsen; Jesper Ryg; Winnie Nielsen; Berit Knold; Nis Nissen; Kim Brixen
Journal:  Patient Educ Couns       Date:  2010-04-18

Review 7.  Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.

Authors:  I Imaz; P Zegarra; J González-Enríquez; B Rubio; R Alcazar; J M Amate
Journal:  Osteoporos Int       Date:  2009-12-05       Impact factor: 4.507

Review 8.  Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review.

Authors:  T Gleeson; M D Iversen; J Avorn; A M Brookhart; J N Katz; E Losina; F May; A R Patrick; W H Shrank; D H Solomon
Journal:  Osteoporos Int       Date:  2009-06-05       Impact factor: 4.507

9.  Community pharmacist-initiated screening program for osteoporosis: randomized controlled trial.

Authors:  N Yuksel; S R Majumdar; C Biggs; R T Tsuyuki
Journal:  Osteoporos Int       Date:  2009-06-05       Impact factor: 4.507

10.  Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study.

Authors:  A Cooper; J Drake; E Brankin
Journal:  Int J Clin Pract       Date:  2006-06-19       Impact factor: 2.503

View more
  25 in total

1.  International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates.

Authors:  A Diez-Perez; K E Naylor; B Abrahamsen; D Agnusdei; M L Brandi; C Cooper; E Dennison; E F Eriksen; D T Gold; N Guañabens; P Hadji; M Hiligsmann; R Horne; R Josse; J A Kanis; B Obermayer-Pietsch; D Prieto-Alhambra; J-Y Reginster; R Rizzoli; S Silverman; M C Zillikens; R Eastell
Journal:  Osteoporos Int       Date:  2017-01-16       Impact factor: 4.507

Review 2.  A systematic review of factors affecting medication adherence among patients with osteoporosis.

Authors:  C T Yeam; S Chia; H C C Tan; Y H Kwan; W Fong; J J B Seng
Journal:  Osteoporos Int       Date:  2018-11-12       Impact factor: 4.507

3.  Systematic screening using FRAX® leads to increased use of, and adherence to, anti-osteoporosis medications: an analysis of the UK SCOOP trial.

Authors:  C M Parsons; N Harvey; L Shepstone; J A Kanis; E Lenaghan; S Clarke; R Fordham; N Gittoes; I Harvey; R Holland; N M Redmond; A Howe; T Marshall; T J Peters; D Torgerson; T W O'Neill; E McCloskey; C Cooper
Journal:  Osteoporos Int       Date:  2019-10-12       Impact factor: 4.507

4.  Potential cost-effectiveness for using patient decision aids to guide osteoporosis treatment.

Authors:  H Penton; M Hiligsmann; M Harrison; J-Y Reginster; A Boonen; N Bansback
Journal:  Osteoporos Int       Date:  2016-05-07       Impact factor: 4.507

Review 5.  Improving drug adherence in osteoporosis: an update on more recent studies.

Authors:  Ayesha Jaleel; Kenneth G Saag; Maria I Danila
Journal:  Ther Adv Musculoskelet Dis       Date:  2018-07-10       Impact factor: 5.346

Review 6.  Bone-seeking agents for the treatment of bone disorders.

Authors:  Jacqueline Cawthray; Ellen Wasan; Kishor Wasan
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

Review 7.  Patient education in osteoporosis prevention: a systematic review focusing on methodological quality of randomised controlled trials.

Authors:  Jana-Carina Morfeld; Vera Vennedey; Dirk Müller; Dawid Pieper; Stephanie Stock
Journal:  Osteoporos Int       Date:  2017-02-24       Impact factor: 4.507

8.  Access to oral osteoporosis drugs among female Medicare Part D beneficiaries.

Authors:  Chia-Wei Lin; Pinar Karaca-Mandic; Jeffrey S McCullough; Lesley Weaver
Journal:  Womens Health Issues       Date:  2014-05-14

9.  Developing Preliminary Steps in a Pharmacist Communication - Patient Outcome Pathway.

Authors:  Bernadette Chevalier; Bernadette M Watson; Michael A Barras; William N Cottrell
Journal:  Can J Hosp Pharm       Date:  2018-08-31

Review 10.  Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.

Authors:  N C W Harvey; E V McCloskey; P J Mitchell; B Dawson-Hughes; D D Pierroz; J-Y Reginster; R Rizzoli; C Cooper; J A Kanis
Journal:  Osteoporos Int       Date:  2017-02-07       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.